Looming Deadlines: Investors in ADMA Biologics and Phreesia Face Critical Legal Decisions

New York, Tuesday, 23 June 2026.
Shareholders of ADMA Biologics and Phreesia have until mid-July 2026 to join securities class actions alleging federal law violations. Rosen Law Firm, the first to file in both cases, highlights potential compensation for investors who purchased shares during specified periods. Phreesia’s stock plummeted ~27% after revealing slowing demand and reduced pharmaceutical marketing commitments. These lawsuits could set precedents for corporate disclosure practices in volatile biotech and healthcare IT sectors.